![]() ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. | ![]() ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers. | ![]() Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. | ![]() Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. | ![]() Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. | |
Founding Date | Founding Date 1981 | Founding Date 2010 | Founding Date 2010 | Founding Date 1982 | Founding Date 2001 |
Type | Type Public | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Waltham, US HQ | Locations Epalinges, CH HQ Greater London, GB New Providence, US San Mateo, US | Locations Los Angeles, US HQ | Locations Morris Plains, US HQ Rödermark, DE | Locations Gent, BE HQ |
Employees | Employees 795% increase | Employees 1162% increase | Employees 27214% decrease | Employees 3666% increase | Employees 3293% decrease |
Valuation ($) | Valuation ($) 788 m | Valuation ($) 540.9 m | Valuation ($) 81.8 m | Valuation ($) 20.3 b | Valuation ($) N/A |
Twitter followers | Twitter followers 1.1 k | Twitter followers N/A | Twitter followers N/A | Twitter followers 583 | Twitter followers 282 |
Alexa Website Rank | Alexa Website Rank 413660 | Alexa Website Rank 281965 | Alexa Website Rank N/A | Alexa Website Rank 374918 | Alexa Website Rank N/A |
Employee Rating | Employee Rating 3.4 | Employee Rating 4.3 | Employee Rating 3.2 | Employee Rating 2.9 | Employee Rating 3.3 |
Financial | |||||
Revenue (est.) | Revenue (est.) $132.3m (FY, 2020) | Revenue (est.) $33.9m (FY, 2021) | Revenue (est.) $225.1m (FY, 2020) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) €85.2m (FY, 2016) |
Cost of goods | Cost of goods N/A | Cost of goods ($1.3m) (FY, 2021) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $32.6m (FY, 2021) | Gross profit N/A | Gross profit $295k (FY, 2019) | Gross profit N/A |
Net income | Net income ($44.4m) (FY, 2020) | Net income ($230m) (FY, 2021) | Net income ($60m) (FY, 2020) | Net income ($357.3m) (FY, 2019) | Net income (€1.1m) (FY, 2016) |
Operating ⚠ | |||||
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 390 (Sep, 2020) | Patents (US) 50 (Q2, 2017) |
Funding | |||||
Total funding raised | Total funding raised $ 56m | Total funding raised $ 526m | Total funding raised $ 172m | Total funding raised $ 30m | Total funding raised $ 498.8m |
ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.
View companyPuma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
View companyImmunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companyAblynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
View company